GRAIL Submits FDA Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the submission of the final module of the Premarket Approval (PMA) ...